IHL Chart Technicals, page-24

Of course Impression is very cheap, and the cheapest valuation outright in the ASX MedCann sphere.
However, I'd be reserved in comparing to AGH as of yet, despite similarities in the space and both partnering with Cannvalate.
AGH does not produce cash iirc and we are, despite making losses we are improving with every quarter.
However last I checked AGH had $18M in cash, which undoubtedly is a big part of why they are able to be valued as high as they are without concerns of running low until years to come.
That being said, these trials are going to be insane if all successful and Impression discloses predictions as to their potential value in $$$, I wouldn't be surprised to see us shooting right up into maybe even overvalued territory.
Quarterly comes out this month correct? Will be interested to see how the dental side is doing as of Q2.